Growth Metrics

Halozyme Therapeutics (HALO) Non-Current Deferred Tax Liability (2022 - 2025)

Halozyme Therapeutics (HALO) has disclosed Non-Current Deferred Tax Liability for 3 consecutive years, with $8.2 million as the latest value for Q3 2025.